Nvidia Expands into Healthcare and Robotics as Political Clouds Gather
11.06.2026 - 18:14:50 | boerse-global.de
The chip giant's shares are treading water near EUR 175 after shedding between 6% and 7% over the past week, with the stock oscillating between EUR 174.82 and EUR 176.10 in recent sessions. Technical indicators suggest a pause rather than a rout: the shares sit roughly 13% below May's all-time high but comfortably above the 52-week low, while the Relative Strength Index of 44.3 signals neither overbought nor oversold conditions. The 50-day moving average at EUR 176.76 has become a near-term resistance, though the 9% cushion above the 200-day line keeps the broader uptrend intact. Option traders, meanwhile, have piled into call contracts, betting that the next leg higher is imminent.
Investors are weighing two distinct expansion narratives. In healthcare, Nvidia has teamed up with AI startup Abridge to build a specialised large language model for clinical documentation. The tool, set to launch later this year, will allow physicians to record patient conversations far more efficiently. The model runs on Nvidia's Nemotron open architecture. Kimberly Powell, who heads the company's healthcare division, sees huge potential in training the system on real clinical data from the outset. Abridge itself was valued at over $5 billion after its latest funding round.
On the hardware side, Nvidia is pushing into physical AI with the unveiling of Alpamayo 2 Super, a platform for autonomous vehicle developers. The strategy goes beyond selling chips: Nvidia aims to supply the entire operating system for machines that perceive and act in the real world. Reports of an expanded alliance with Hyundai underscore the ambition, placing the company's robotics credentials alongside a major industrial partner. CEO Jensen Huang has described the move as part of building a full ecosystem rather than simply delivering components.
Should investors sell immediately? Or is it worth buying Nvidia?
Yet the expansionary push unfolds against a backdrop of political friction. Huang declined a summons from the US Senate, where Senator Elizabeth Warren wanted to quiz him on Nvidia's China business. He instead offered to host discussions at the company's headquarters. Washington has tightened export controls on high-performance chips to China, and Nvidia is already planning the second quarter without any revenue from Chinese data centres. To help fill that gap, software giant Oracle has committed roughly $70 billion to new data centre construction over the coming year, a massive investment that should buoy demand for Nvidia and AMD hardware.
Fundamentally, the company continues to deliver. First-quarter revenue surged to $81.6 billion, while the gross margin hit a robust 75%. Management has guided for $91 billion in the current quarter. Even so, the stock's recent weakness reflects broader macro jitters, including persistent US inflation at 4.2% and rising tensions in the Gulf. Huang himself has struck a cautious note on supply, acknowledging that Nvidia's capacity is sufficient for strong growth but remains constrained — a tension that keeps the market guessing.
The question for investors is whether the physical AI and healthcare bets can justify a valuation that has already priced in data centre dominance. With stock volatility above 41%, the market is demanding concrete proof. The current pullback looks more like a healthy consolidation than a trend reversal, but Nvidia must now show that its new frontiers can generate the same earnings momentum that made the data centre business a powerhouse.
Ad
Nvidia Stock: New Analysis - 11 June
Fresh Nvidia information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
